EN DE
Watch Simulations Plus Inc for free: we tell you when fair value or trend changes.
Data-driven stock valuation

Simulations Plus Inc (SLP) fair value: what the stock is really worth

As of Oct 7, 2026: fair value (intrinsic value) of Simulations Plus Inc stock $15.08, price $18.50, that is 18.5% below the price, quality 69 out of 100. Rating: overvalued. Calculated from audited financials with 7 of our 26 valuation models and 37 quality factors, updated daily.

  1. Keep an eye on it?Free in your watchlist: 5 stocks without an account, 10 with one Yes, for free

Healthcare US

SP Simulations Plus Inc logo Some data Nov 4, 2026

Simulations Plus Inc

SLP · US
Overvalued / Monitor

Our calculation puts a fair price 18% below what the stock costs today.

Quality 69/100
Low debt
Generates free cash flow
Positive coverage
Profit last quarter +47% vs. a year ago.
Mixed Growth (revenue 5y +13.7 %/yr in USD)
Thin margins · 9.9% net margin (TTM)
Mixed vs. peers (7/14)
Insiders sold $220,776 (6M)
Some data
Fair value $15.08 · Overvalued (−18.5%)
Narrow moat 42/100 · thin data
Watch Simulations Plus Inc for free: we tell you when fair value or trend changes. Watch for free

What runs behind every stock

26 valuation models 8 families, DCF to NCAV 37 quality factors margins, balance sheet, cashflow, debt 6 AI factors moat, what no ratio measures 2,000+ data points verified, per stock, median

69 individual criteria per stock, every one traceable See the method →

Price vs Fair Value

$66.10 $11.36 Fair Value $15.08 Jul 2021 Oct 2026

White line = price, green steps = our fair value per fiscal year. As of Nov 4, 2026.

How to read this chart

60‑month range $11.36 – $66.10 · fair‑value band $9.46 – $22.51 · the $18.50 price screens above the $15.08 fair value. Green steps = our fair value per fiscal year (point-in-time, no hindsight). As of Nov 4, 2026.

Follow Simulations Plus in your weekly email

Every Wednesday you see whether Simulations Plus is on track or worth a review, plus price against fair value. Free, up to 3 stocks.

We send you a confirmation link. Unsubscribe with one click.

Which stocks are undervalued right now? Check free Discover now →

Company profile

Simulations Plus, Inc. develops drug discovery and development software for modeling and simulation, and prediction of molecular properties utilizing artificial intelligence and machine learning based technology worldwide. It operates through Software and Services segments.

Show moreShow less

The company offers GastroPlus, which predicts absorption, biopharmaceutics, pharmacokinetics, and pharmacodynamics in humans and animals; and DDDPlus and MembranePlus simulation products.

It also provides products based on mechanistic and mathematical models, such as DILIsym, NAFLDsym, ILDsym, IPFsym, RENAsym, MITOsym, OBESITYsym, and Thales products.

In addition, the company offers Absorption, Distribution, Metabolism, Excretion, and Toxicity (ADMET) predictor for chemistry-based computer program that takes molecular structures as inputs and predicts their properties; and MedChem Designer, as well as MonolixSuite products for modeling and simulation that allows for population analyses, rapid clinical trial data analyses, and regulatory submissions.

Further, it provides clinical-pharmacology-based consulting services, which includes population pharmacokinetic and pharmacodynamic modeling, exposure-response analyses, clinical trial simulations, data programming, and technical writing services in support of regulatory submissions; and early drug discovery services.

Additionally, the company offers creative and insightful consulting services to support its quantitative systems pharmacology and other modeling systems.

The company serves pharmaceutical, biotechnology, agrochemical, cosmetics, and food industry companies, as well as academic and regulatory agencies. Simulations Plus, Inc. was incorporated in 1996 and is headquartered in Research Triangle Park, North Carolina.

Stock analysis

Simulations Plus Inc (SLP) currently trades at $18.50, while our model-based Fair Value estimate is $15.08, 18% below the price, so the stock looks overvalued today.

Show more

Valuation

Bull case: the DCF Models group reads highest at a median of $15.64 per share, and 0 of the 7 models we run sit above the $18.50 price.

Bear case: the Asset-Based group reads lowest at $2.20, and 7 of the 7 models stay below the price. Data coverage for this calculation is medium.

Scenario range: $9.46 (bear) to $22.51 (bull), the price of $18.50 sits inside it. Bear and bull are the same models on cautious and optimistic assumptions, a range, not a price target.

Quality & growth

The Quality Score stands at 69/100 (solid quality), in the Healthcare sector.

Mixed Growth: Revenue is growing, but margins or cash flow do not fully confirm the trend.

Simulations Plus Inc reported revenue of $79.2M in FY2025 versus $46.5M in FY2021, a compound +14.3%/yr. Reported net income was −$64.7M in FY2025.

Key figures

Market cap $374M Small · P/E ratio 46.3 · P/S ratio 4.56 · EPS (TTM) $0.4000 · Net margin 9.9% · Return on equity 6.2% · Return on assets (EBIT) −6.4% · Operating margin 22.8%.

Competitive moat

Our AI-assisted moat analysis scores the competitive advantage at 42 out of 100 (low confidence).

What moves the price

The share trades about 11% below its 52-week high and 63% above its 52-week low, currently above its 200-day average.

For context, the median of 10 Healthcare peers we cover trades at 3% fair-value upside, at −18%, SLP screens richer than that median.

Fair Value models

Bear $9.46 Fair Value $15.08 Bull $22.51
Price $18.50 · Downside -18.5%
Model ⓘEach model values the company its own way (discounted cash flow, earnings, assets, dividends). The fair value above starts from their evidence-weighted blend, not from a single model. In cyclical trough or peak years, after dilution or a stock split it is adjusted afterwards, so it can sit above or below the models. Based on fiscal year 2025 figures (about 12 months old). Earnings retained since then ($0.4000 per share) are deliberately not added. Bear ⓘBear = the cautious scenario: the same model computed with conservative anchors (lower growth, margins and valuation multiples). Together with Bull it frames a plausible valuation range, not a price target.BaseBull ⓘBull = the optimistic scenario: the same model computed with favourable anchors (higher growth, margins and valuation multiples). Together with Bear it frames a plausible valuation range, not a price target. If a model's bull case is above four times its base value, the table shows that limit with a > sign (like the overall Bull above): beyond it no assumption holds. Coverage ⓘCoverage = how well-backed THIS model's estimate is for this stock (0–100): how complete and reliable its input data are, and how well the model fits the company. The final Fair Value is an evidence-weighted blend, so better-evidenced models count more. Green ≥70, amber 50–69, grey below 50.
Best data coverage
FCF DCF $10.10 $16.30 $26.09 79
Growth DCF $9.85 $15.08 $22.51 78
Rev-Margin DCF $9.46 $15.47 $23.60 72
All 7 models by family
DCF Models
FCF DCF $10.10 $16.30 $26.09 79
5Y Revenue Exit $9.46 $15.64 $24.17 71
10Y Revenue Exit $9.36 $14.92 $23.73 65
Multiples
EV/Revenue $9.33 $12.69 $16.05 54
Asset-Based
NCAV (Graham) $1.45 $2.20 $2.75 54
Growth DCF
Growth DCF $9.85 $15.08 $22.51 78
Rev-Margin DCF $9.46 $15.47 $23.60 72

Open the full fair value analysis →

Quality Score breakdown

Overall quality 69/100

It rates the business: profits, how they develop, real cash, balance sheet, investing and share count.

Profitability 21
How much profit the company makes from its sales and capital
Quality Growth 36
Are margins and returns getting better?
Cashflow 90
Do the profits arrive as real cash?
Financial strength 94
Debt, balance sheet and risk of trouble
Investment 100
Does it invest with discipline instead of growing at any price?
Low Volatility 34
How calm the share price moves, does not count
Price momentum 63
Price momentum of the last 3 to 12 months, does not count
Near the 52-week high 61
Distance to the 52-week high, does not count
New shares 80
Buys back shares or issues new ones?

Open the full quality analysis →

Insider trades

In the last 6 months, 2 officers or directors sold shares worth $220,776 and none bought.

  • SaleJohn Anthony DiBella IIChief Revenue Officer5× since Apr 15, 2026: 5,000 shares, avg. $16.30$81,490Aug 3, 202610b5-1 plan
  • SaleVirginia E Woltosz10% owner2× since Jun 1, 2026: 19,177 shares, avg. $17.65$338,474Jul 1, 202610b5-1 plan
  • SaleJill Fiedler-KellyPresident, Services Solutions3× since May 11, 2026: 9,400 shares, avg. $17.83$167,636Jun 16, 202610b5-1 plan
  • SaleWalter S WoltoszDirector, 10% owner15,000 shares at $15.13$226,950May 4, 202610b5-1 plan
  • SaleLisa LaVangeDirector866 shares at $16.91$14,644Dec 1, 202510b5-1 plan

Plus 10 other filings such as grants, option exercises or tax withholding. They are not market purchases or sales.

Sales are often planned (taxes, diversification, 10b5-1 plans). Purchases with their own money are seen as the stronger sign. For information only: not part of the quality score or Fair Value.

Source: SEC Form 4, as of Nov 6, 2026. All filings at the SEC ↗

Revenue & earnings trend

Growth Quality ⓘGrowth is valuable only when reinvestment earns attractive returns (Aswath Damodaran): sustainable growth depends on return on capital, reinvestment and efficiency. Basis: total company revenue over the periods shown on the cards (3Y/5Y/all years), not per share, so a merger can show up as a growth jump; per-share earnings growth is in the value-creation card. 81/100
Revenue is growing, but margins or cash flow do not fully confirm the trend.
Revenue growth 1 year
+13.1%
Revenue growth 3 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+13.7%
Revenue growth 5 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+13.7%
Start year 2020 (pandemic). Over 10 years: +15.8% a year
Revenue growth 29 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+12.5%
Profit margin (trend) ⓘOperating margin then vs now, from reported annual statements. A falling margin after a boom year is the classic peak-earnings signal: the growth rate then leans on an inflated base.
27.9% (2020) → −89.3% (2025)
What shareholders gained per year ⓘWe only publish this rate when it is defensible. Reason: fiscal 2025 is a loss year, no rate is defined from a loss
not computed

Growth Forecast

Price in line with expectations
The price assumes about as much growth as the company has delivered so far.
What the price assumes ⓘThis turns our valuation around: instead of asking what the share is worth, it asks what growth the current price requires. It uses the cash the company keeps after all spending (free cash flow), the same discount rate as our models, five years of growth, then slowing evenly to 2 % a year by year ten. Compared with the analysts' sales forecasts extended to the same five years (at least three analysts, for context only, it does not enter the Fair Value): within 3 percentage points counts as "in line" (amber), below that little optimism (green), above that a lot of optimism (red).
+15.1%
Yearly growth needed for the next five years to justify today's price.
What forecasts expect
n/a
No analyst forecast available.
After inflation (USA: IMF forecast 2.4% a year to 2030, 3.1% from 2016 to 2025) that is about +12.4% a year for the price.

SLP screens overvalued: fair value 18% below the price. Compare with Veeva Systems Inc →

Earlier news

News mood ⓘNews mood, the average tone of recent news (86 articles), rated against how stocks are usually covered. 🚀 Hype = unusually upbeat · 🙂 Positive = above average · 😐 Neutral = typical · 🙁 Negative = below average · 😨 Very negative = unusually downbeat. It reflects the tone of coverage, not our valuation. Positive
Recent news coverage is more positive than average.

Compare Simulations Plus Inc with another stock

Price, fair value, quality and upside side by side.

Free, no sign-up

Peer GroupⓘHow this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.Health Information Services · 118 stocks

Beats the industry median on 7/14 measures
A mixed picture versus its industry peers.
Valuation
Quality Score 69 · Top 25%
Fair Value upside −18.5% · Above median
Profitability
Return on equity (12 months) 6.2% · Above median
Return on assets −49.1% · Bottom 25%
Net margin (12 months) 9.9% · Above median
Operating margin (12 months) 22.8% · Top 25%
Growth and dividend
Revenue growth (quarter YoY) 7.5% · Below median
Balance sheet
Debt / equity 0.03× · Below median

Valuation Multiplesvs Health Information Services median · lower = cheaper

P/E (12 months) 46.3× · Priciest 25%
P/B 3.00× · Pricier than median
P/S (12 months) 4.56× · Pricier than median
Price / free cash flow (fiscal year) 21.5× · Cheaper than median
EV/EBITDA 23.1× · Pricier than median
PEG 9.88× · Priciest 25%

Strength profile in five axes (Snowflake)

VALUEFUTUREPASTHEALTHDIVIDEND
This stock
VALUEFUTUREPASTHEALTHDIVIDEND
Sector peers
VALUE (fair-value potential)9 · sector 0
FUTURE (revenue growth)38 · sector 44
PAST (return on equity)25 · sector 10
HEALTH (low debt)99 · sector 98
DIVIDEND (yield)0 · sector 37

Context: sector, industry, market

Values & ESG

Does this company touch areas you may want to avoid? The classification is inferred from sector and industry.

None of the checked exposures detected

Similar stocks

10 more Health Information Services stocks, each showing price versus our Fair Value estimate.

Stock Price Fair Value vs Fair Value Compare
Doximity, Inc DOCS $32.51 $38.14 +17% vs SLP
Inventurus Knowledge Solutions Limited IKS ₹1,657 ₹1,933 +17% vs SLP
HealthEquity, Inc HQY $103.63 $119.72 +16% vs SLP
Veeva Systems Inc VEEV $303.73 $341.69 +13% vs SLP
Waystar Holding WAY $28.35 $29.10 +3% vs SLP
Hinge Health, Inc HNGE $115.76 $51.25 −56% vs SLP
Pro Medicus Limited PME A$205.13 A$85.12 −59% vs SLP
BrightSpring Health Services, Inc BTSG $67.15 $25.72 −62% vs SLP
XtalPi Holdings 2228 HK$6.13 HK$1.53 −75% vs SLP
Privia Health Group PRVA $24.42 $5.52 −77% vs SLP

Explore undervalued stocks

More undervalued Healthcare stocks →

All undervalued stocks TechnologyFinancial ServicesHealthcareConsumer CyclicalConsumer DefensiveCommunication ServicesIndustrialsEnergyBasic MaterialsReal EstateUtilities Deeply Undervalued StocksUndervalued High-Quality StocksUndervalued Blue-Chip StocksUndervalued Small-Cap StocksUndervalued Dividend Stocks

Try a ready-made strategy

Pick a strategy and jump into the live analysis with that exact screen applied.

🥇 Backtested Best 🏆 Big Names 💎 Quality on Sale 🚀 Profitable Growth 🧊 Quality Compounders 💵 Dividend Stars 📈 Strong Momentum 📉 Fallen Angels ⚖️ Deeply Undervalued 🔍 Small-Cap Gems 🏰 Moat at a Fair Price 💼 Insider Buying 🎩 Buffett-Style Quality 📚 Peter Lynch GARP 🧮 Greenblatt Magic Formula 🛡️ Graham Defensive

Discover tools

Stock screenerFilter by region, size and sector Compare toolTwo stocks side by side Evidence & backtest34 years, failed companies included Financial calculatorsDCF, Graham, PEG and more
Run the numbers yourself: free valuation calculators
DCF CalculatorP/E Ratio CalculatorPEG Ratio CalculatorGraham NumberPeter Lynch FormulaDDM CalculatorIntrinsic ValueIntrinsic vs Extrinsic ValueP/E Ratio by Sector
For bloggers & editors: embed code + live data

For bloggers, editors and developers: paste this into your site or blog (a “Custom HTML” block in WordPress), it shows the current fair value and links back here. Free, plain HTML, and welcome. Full data streams (CSV/JSON) at /developers.

Simulations Plus Inc: fair value per Fair Value Calculator

Cite: Fair Value Calculator (2026). "Simulations Plus Inc Fair Value". https://www.fairvalue-calculator.com/stock/SLP.US

Frequently asked questions

Is Simulations Plus Inc (SLP) overvalued or undervalued?
As of Nov 4, 2026, our model estimates a fair value of $15.08 versus the last price from Oct 7, 2026 of $18.50, about 18% lower (overvalued).
What is the fair value of SLP?
Our model-based fair value for Simulations Plus Inc is $15.08 (as of Nov 4, 2026), built from audited fundamentals. Last price (from Oct 7, 2026): $18.50.
What is the quality score of SLP?
Simulations Plus Inc has a Quality Score of 69/100. It measures business quality (profitability, growth, cash flow, balance-sheet strength, investment discipline, share issuance). Market factors such as price momentum and volatility do not enter the number; they are shown separately in the detail view.
What is the price target for Simulations Plus Inc (SLP)?
Our model-based price target is the fair value of $15.08 (as of Nov 4, 2026) from 7 valuation models. Cautious scenario $9.46, optimistic scenario $22.51. It is a calculation from audited fundamentals, not an analyst target.
What is the Simulations Plus Inc stock forecast for 2026?
Our models put fair value at $15.08, about 18% lower versus the last price from Oct 7, 2026 of $18.50 (overvalued). Cautious scenario $9.46, optimistic scenario $22.51. The calculation is refreshed regularly with new filings.
What is the revenue of Simulations Plus Inc (SLP)?
Simulations Plus Inc reported trailing-twelve-month revenue of about $82.1M (latest available figure, as of Nov 4, 2026).
What growth is priced into Simulations Plus Inc (SLP)?
For today's price to be fair in a discounted-cash-flow model, Simulations Plus Inc would have to grow free cash flow by +15.1 % per year for five years (discount rate 12.1 %, then slowing evenly to 2 % perpetual growth by year ten). Over the last 5 years revenue grew +13.7 % per year. As of Nov 4, 2026.
What discount rate (WACC) does the fair value of SLP use?
Our models discount Simulations Plus Inc at 12.1 %: a base by market capitalisation (small), damped by beta 1.32, country premium for USA. The same rate applies in all 26 models.
What is a reverse DCF?
A reverse DCF turns the usual calculation around. Instead of deriving a value from assumptions, it takes today's price as given and asks: what free-cash-flow growth would a company have to deliver for exactly this price to be fair? The result is not a forecast but the expectation already priced in. For Simulations Plus Inc that is +15.1 % per year a year over ten years, using the same discount rate (12.1 %) and the same formula as our fair value.
How much growth has Simulations Plus Inc (SLP) delivered so far?
Over the past 5 years revenue at Simulations Plus Inc grew +13.7 % a year. The price currently implies +15.1 % per year free-cash-flow growth a year. Comparing the two shows how much confidence is in the price: if it demands more than has been delivered, the business has to accelerate for the maths to work.
How fast is the sector of Simulations Plus Inc (SLP) growing?
The median revenue growth in the sector is +6.2 % a year. That is the yardstick for the growth priced into Simulations Plus Inc (+15.1 % per year a year): it shows whether the expectation is within the usual range or beyond it.
What is the free cash flow yield of Simulations Plus Inc (SLP)?
The free-cash-flow yield on the price is 4.65 %: that much free cash flow Simulations Plus Inc produces per unit of market value. When it exceeds the discount rate of our models (12.1 %), the business already earns more than its cost of capital demands, and the price needs little additional growth.
What is the intrinsic value of Simulations Plus Inc (SLP)?
Intrinsic value and fair value mean the same thing: what the business is worth on its numbers, independent of the share price. For Simulations Plus Inc it is $15.08 per share (as of Nov 4, 2026), against a price of $18.50. It is the blended result of 7 valuation models (cash flow, earnings, asset, dividend).
Is Simulations Plus Inc stock overvalued or undervalued in 2026?
As of Nov 4, 2026, SLP trades above its calculated fair value: price $18.50, fair value $15.08, a gap of about −18% (overvalued). The calculation is refreshed with each new quarterly report, so the verdict can change during the year.
Is fair value the same as the market price of SLP?
No. The price is what the market pays today ($18.50); the fair value is what the company's own numbers justify ($15.08). For Simulations Plus Inc the two are $3.42 per share apart. That gap is exactly why we show both numbers side by side.
How much is Simulations Plus Inc worth?
The market values Simulations Plus Inc at about $374M (market capitalisation, as of Nov 4, 2026). Per share that is $18.50; our models calculate a fair value of $15.08 per share.
What do the bullish and bearish scenarios say about SLP?
Our models span a range for Simulations Plus Inc: cautious scenario $9.46, base $15.08, optimistic $22.51 per share (as of Nov 4, 2026, price $18.50). The range comes from different growth and margin assumptions, not from analyst opinions.
What is the P/E ratio of SLP?
Simulations Plus Inc trades at a price-to-earnings ratio of 46.3 (as of Nov 4, 2026). A P/E on its own says little: it compares the price with ONE year of profit, while our fair value of $15.08 is built from several models across several years. Median P/E at fiscal year-end, 9 fiscal years (2016 to 2024), reported earnings: 76.0. Other multiples: PEG 9.9, P/B 3.0, P/S 4.6, EV/EBITDA 23.1.
What is the PEG ratio of SLP?
The PEG ratio of Simulations Plus Inc is 9.88 (P/E divided by earnings growth, as of Nov 4, 2026). That is above 1, so the growth is already paid for in the price.
How solid is the balance sheet of Simulations Plus Inc (SLP)?
Balance-sheet figures for Simulations Plus Inc (as of Nov 4, 2026): return on equity 6.2%, debt of 0.03 per unit of equity. They feed the Quality Score of 69/100, which measures business quality independently of the share price.
How far is SLP from its 52-week high?
Simulations Plus Inc trades at $18.50, about 11% below its 52-week high of $20.84 and 63% above the low of $11.36 (as of Oct 7, 2026). Distance from the high says nothing about value: that is what the fair value of $15.08 is for.
Which stocks are comparable to Simulations Plus Inc?
From the same area (Healthcare) we also value Veeva Systems Inc, Pro Medicus Limited, BrightSpring Health Services, Inc, Hinge Health, Inc, among others. Each of them has its own fair-value calculation on this site using the same models, so the comparison is like for like.
Is Simulations Plus Inc stock attractive at the current price?
The data as of Nov 4, 2026: price $18.50, calculated fair value $15.08 (−18%), Quality Score 69/100, from 7 models. Whether that fits your horizon and risk tolerance is your call. We provide the calculation, not investment advice.
How is the fair value of SLP calculated?
We run Simulations Plus Inc through 7 models from four families: discounted cash flow, earnings models, asset and balance-sheet models, and dividend models. Every model gets the same audited fundamentals; the result is the weighted average of $15.08, with the spread shown as a cautious and an optimistic scenario.
Is it still worth investing in stocks now?
The global stock market currently sits 12.7% above its aggregate fair value. Simulations Plus Inc itself currently trades above fair value. An expensive market is no reason to stay out and no reason to buy everything at once: keep a broad savings plan running, buy single stocks only with money you can do without, and hold part of your money liquid while the market is high. The full picture including sectors is on is it worth investing now.
What is the share price of Simulations Plus Inc (SLP)?
The latest price we hold is from Oct 7, 2026 and stands at $18.50. Our model-based fair value is $15.08, about 18% lower (overvalued). We carry closing prices from our data provider, not a live tick.
What should I pay attention to with Simulations Plus Inc right now?
Solid but not exceptional quality (69/100) and above fair value, neither a clear bargain nor a standout compounder. A fairly wide model range ($9.46 to $22.51) leaves room in how you read the outcome.
Where does the earnings growth of Simulations Plus Inc (SLP) come from?
Earnings per share at Simulations Plus Inc grew +9.1 % a year from 2014 to 2025. Broken into its drivers: revenue per share +14.8 %, EBIT margin −12.4 %, tax rate +2.4 %, residual (interest, one-offs) +5.9 %. The four rates multiply to the earnings growth rate, they do not add up. Start and end are three-year averages so a single exceptional year does not distort the result.

Key figures of Simulations Plus Inc

How large is the market capitalisation of Simulations Plus Inc (SLP)?
The market capitalisation of Simulations Plus Inc is $374M. The stock-market value of the whole company: share price times number of shares. It is what the market asks for the entire business today.
What is the P/S ratio of Simulations Plus Inc (SLP)?
The price-to-sales ratio of Simulations Plus Inc is 4.56 (last twelve months). Price to sales: market value relative to yearly revenue. Useful when profit is thin or distorted.
What are the earnings per share of Simulations Plus Inc (SLP)?
Earnings per share at Simulations Plus Inc are $0.4000 (price ÷ EPS = P/E 46.3). Earnings per share over the last twelve months: total profit spread across every single share.
What is the net margin of Simulations Plus Inc (SLP)?
The net margin of Simulations Plus Inc is 9.9% (last twelve months). How much of every unit of revenue ends up as profit. 10% means 10 cents of profit per dollar of sales.
What is the return on equity of Simulations Plus Inc (SLP)?
The return on equity (ROE) of Simulations Plus Inc is 6.2% (last twelve months). Profit relative to shareholders' equity, how efficiently the company works with its owners' money.
What is the EBIT return on assets of Simulations Plus Inc (SLP)?
On an EBIT basis the return on assets of Simulations Plus Inc is −6.4% (avg 5y). Operating profit (EBIT) relative to everything the company owns, as a multi-year average. It describes the business model rather than one good or bad year.
What is the operating margin of Simulations Plus Inc (SLP)?
The operating margin of Simulations Plus Inc is 22.8% (last twelve months). Profit from the core business (before interest and taxes) relative to revenue.
How fast is revenue growing at Simulations Plus Inc (SLP)?
Revenue at Simulations Plus Inc is growing +7.5% versus a year earlier (3y avg +13.7%). How much revenue grew versus a year earlier (YoY). The 3-year average next to it puts the single year in context.
How fast are earnings growing at Simulations Plus Inc (SLP)?
Earnings per share at Simulations Plus Inc are growing +46.7% versus a year earlier. How much earnings per share grew versus a year earlier.
How much net cash does Simulations Plus Inc (SLP) hold?
Simulations Plus Inc holds more cash than debt, $30.2M net (fiscal year 2025). The company holds more cash than debt, a safety cushion.
Free · no account needed

Watch Simulations Plus Inc in the live analysis

One click puts Simulations Plus Inc on your watchlist: fair value and trend at a glance, plus comparison, the diversification check and the 27,000+ stock screener.

Watch for free →

Zero risk: nothing is ever charged. Your watchlist is yours, with or without an account.